CereCura Nanotherapeutics is a Vancouver-based spin-out from the University of British Columbia that uses lipid nanoparticle–ribonucleic acid (LNP-RNA) technology—first popularized in COVID-19 vaccines—to ferry genetic instructions into the brain. Its lead candidate targets neuronopathic Gaucher disease by supplying mRNA for the missing enzyme glucocerebrosidase, and the same platform is being advanced for Alzheimer’s and Parkinson’s indications. In pre-clinical studies the company has successfully delivered multiple proteins to rodent brains with a week-long half-life, overcoming the blood-brain barrier that limits conventional enzyme replacement therapies. The science is guided by LNP pioneer and co-founder Pieter Cullis alongside CEO and neuroscientist Louis-Philippe Bernier. Management intends to build a pipeline of pre-clinically validated assets that can move quickly toward clinical development. CereCura has raised C$2.2 million in equity financing to date and secured more than C$4 million in government grants, funding upcoming efficacy work in rodents and larger animals.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025